Aeterna Zentaris Announces Filing of Preliminary Base Shelf Prospectus
December 30 2015 - 4:06PM
Business Wire
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”)
today announced that it has filed a preliminary short form base
shelf prospectus (the “Shelf Prospectus”) with the securities
regulatory authorities in each of the provinces of Canada, and a
corresponding shelf registration statement on Form F-10 with the
U.S. Securities and Exchange Commission (the “SEC”) under the
U.S./Canada Multijurisdictional Disclosure System.
The Shelf Prospectus and corresponding shelf registration
statement, when made final or effective, will allow the Company to
offer up to US$150,000,000 of common shares, preferred shares, debt
securities, subscription receipts, warrants or units comprised of
one or more of such securities during the period that the Shelf
Prospectus is effective.
Commenting on the filing, David A. Dodd, Chairman, President and
Chief Executive Officer of the Company stated, “The Shelf
Prospectus is intended to give us the ability to access new capital
in the future. Taking into account our current operations and
capital requirements, the offering we completed earlier this month
is expected to provide sufficient capital to see us through the
first quarter of 2017. As such, we have no immediate intention to
conduct another offering. Our existing shelf prospectus and
registration statement will expire in April 2016 and we felt that
it was prudent to file a new one to ensure that our ability to
raise capital is not curtailed or interrupted after the current
shelf expires.”
The specific terms of any future offering under the Shelf
Prospectus will be established at the time of such offering. At the
time any of the securities covered by the Shelf Prospectus are
offered for sale, a prospectus supplement containing specific
information about the terms of such offering will be filed with
applicable Canadian securities regulatory authorities and the
SEC.
Upon the issuance of a receipt by the Canadian securities
regulatory authorities for the final Shelf Prospectus and the
effectiveness of the corresponding registration statement on Form
F-10 of which the Shelf Prospectus forms part, the final Shelf
Prospectus will supersede and replace the Company’s existing short
form base shelf prospectus dated March 13, 2014 and the
corresponding registration statement.
The new shelf registration statement filed today with the SEC
has not yet become effective. No securities may be sold, nor
may offers to buy be accepted, prior to the time the registration
statement becomes effective. This news release shall not
constitute an offer to sell or a solicitation of an offer to buy,
nor shall there be any sale of these securities in any jurisdiction
in which an offer, solicitation or sale would be unlawful prior to
registration or qualifications under the securities laws of any
such jurisdiction.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women’s health. We are engaged in drug
development activities and in the promotion of products for others.
We are now conducting Phase 3 studies of two internally developed
compounds. The focus of our business development efforts is the
acquisition of licenses to products that are relevant to our
therapeutic areas of focus. We also intend to license out certain
commercial rights of internally developed products to licensees in
territories where such out-licensing would enable us to ensure
development, registration and launch of our product candidates. Our
goal is to become a growth-oriented specialty biopharmaceutical
company by pursuing successful development and commercialization of
our product portfolio, achieving successful commercial presence and
growth, while consistently delivering value to our shareholders,
employees and the medical providers and patients who will benefit
from our products. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking
statements made pursuant to the safe harbor provisions of the US
Securities Litigation Reform Act of 1995. Specifically, the
statement that the Company believes that it has sufficient capital
to fund its operations through the first quarter of 2017 is a
forward-looking statement. Forward-looking statements involve known
and unknown risks and uncertainties that could cause the Company's
actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the assumptions used in developing the Company’s
forecasts of cash revenue and expenditures, the availability of
funds and resources to pursue research and development projects and
clinical trials, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process, the
potential inability to protect our intellectual property, the
potential of liability arising from shareholder lawsuits and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and US
securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to place undue reliance on these forward-looking
statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce the result of any
revisions to the forward-looking statement contained herein to
reflect future results, events or developments, unless required to
do so by a governmental authority or by applicable law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151230005539/en/
Aeterna Zentaris Inc.Philip Theodore, 843-900-3223Senior Vice
Presidentptheodore@aezsinc.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024